MX2020009851A - Anticuerpos anti-pfrh5 y fragmentos de unión al antígeno de estos. - Google Patents

Anticuerpos anti-pfrh5 y fragmentos de unión al antígeno de estos.

Info

Publication number
MX2020009851A
MX2020009851A MX2020009851A MX2020009851A MX2020009851A MX 2020009851 A MX2020009851 A MX 2020009851A MX 2020009851 A MX2020009851 A MX 2020009851A MX 2020009851 A MX2020009851 A MX 2020009851A MX 2020009851 A MX2020009851 A MX 2020009851A
Authority
MX
Mexico
Prior art keywords
antigen
binding fragments
antibodies
compositions
pfrh5
Prior art date
Application number
MX2020009851A
Other languages
English (en)
Inventor
Lisa Purcell
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2020009851A publication Critical patent/MX2020009851A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención incluye anticuerpos y fragmentos de unión al antígeno de estos que se unen específicamente al homólogo 5 de la proteína de unión a reticulocitos de Plasmodium falciparum (PfRH5), composiciones de estos y métodos para preparar dichos anticuerpos, fragmentos y composiciones. El método y las composiciones para tratar, prevenir o diagnosticar la infección por Plasmodium falciparum y la malaria también forman parte de la presente invención.
MX2020009851A 2018-03-26 2019-03-22 Anticuerpos anti-pfrh5 y fragmentos de unión al antígeno de estos. MX2020009851A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862648259P 2018-03-26 2018-03-26
PCT/US2019/023734 WO2019190931A1 (en) 2018-03-26 2019-03-22 Anti-pfrh5 antibodies and antigen-binding fragments thereof

Publications (1)

Publication Number Publication Date
MX2020009851A true MX2020009851A (es) 2020-11-09

Family

ID=66041796

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009851A MX2020009851A (es) 2018-03-26 2019-03-22 Anticuerpos anti-pfrh5 y fragmentos de unión al antígeno de estos.

Country Status (17)

Country Link
US (3) US11667701B2 (es)
EP (1) EP3774893A1 (es)
JP (1) JP7382950B2 (es)
KR (1) KR20200135435A (es)
CN (1) CN112088166A (es)
AU (1) AU2019241978A1 (es)
BR (1) BR112020018691A2 (es)
CA (1) CA3094981A1 (es)
CL (1) CL2020002449A1 (es)
CO (1) CO2020012638A2 (es)
EA (1) EA202092281A1 (es)
IL (1) IL277296A (es)
MA (1) MA52175A (es)
MX (1) MX2020009851A (es)
PH (1) PH12020500662A1 (es)
SG (1) SG11202008848XA (es)
WO (1) WO2019190931A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020009851A (es) 2018-03-26 2020-11-09 Regeneron Pharma Anticuerpos anti-pfrh5 y fragmentos de unión al antígeno de estos.
JP2023533253A (ja) * 2020-07-02 2023-08-02 マブリティクス， インコーポレイテッド 細胞結合タンパク質および使用の方法
KR20240006505A (ko) * 2021-03-12 2024-01-15 이칸 스쿨 오브 메디슨 엣 마운트 시나이 Bk 바이러스에 대한 중화 단클론성 항체
CN113045653A (zh) * 2021-03-22 2021-06-29 中国人民解放军空军军医大学 抑制疟原虫感染的单克隆抗体及其制备方法和应用
WO2024243355A1 (en) * 2023-05-24 2024-11-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that target the rh5 complex of blood-stage plasmodium falciparum

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
FI92882C (fi) 1992-12-29 1995-01-10 Medix Biochemica Ab Oy Kertakäyttöinen testiliuska ja menetelmä sen valmistamiseksi
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2550933A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
CN103260641B (zh) * 2010-11-09 2015-09-23 沃尔特及伊莱萨霍尔医学研究院 疟疾的治疗和预防
SG10201700360VA (en) * 2012-03-16 2017-03-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JP6510518B2 (ja) 2013-08-01 2019-05-08 アジェンシス，インコーポレイテッド Ｃｄ３７タンパク質に結合する抗体薬物結合体（ａｄｃ）
DE112014005975T5 (de) 2013-12-17 2016-09-15 Kymab Limited Menschliche Ziele
WO2015092394A1 (en) 2013-12-17 2015-06-25 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
CN107207594B (zh) 2014-12-23 2019-05-07 百时美施贵宝公司 针对tigit的抗体
TWI710573B (zh) * 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
MX2020009851A (es) 2018-03-26 2020-11-09 Regeneron Pharma Anticuerpos anti-pfrh5 y fragmentos de unión al antígeno de estos.

Also Published As

Publication number Publication date
WO2019190931A1 (en) 2019-10-03
US20210024625A1 (en) 2021-01-28
EP3774893A1 (en) 2021-02-17
KR20200135435A (ko) 2020-12-02
EA202092281A1 (ru) 2021-01-22
IL277296A (en) 2020-10-29
PH12020500662A1 (en) 2021-06-28
US20230365668A1 (en) 2023-11-16
MA52175A (fr) 2021-02-17
US11667701B2 (en) 2023-06-06
BR112020018691A2 (pt) 2021-01-05
JP2021519086A (ja) 2021-08-10
US20240400663A1 (en) 2024-12-05
CN112088166A (zh) 2020-12-15
JP7382950B2 (ja) 2023-11-17
AU2019241978A1 (en) 2020-11-05
US12091449B2 (en) 2024-09-17
CA3094981A1 (en) 2019-10-03
CO2020012638A2 (es) 2020-10-30
CL2020002449A1 (es) 2021-01-29
SG11202008848XA (en) 2020-10-29

Similar Documents

Publication Publication Date Title
PH12020500662A1 (en) Anti-pfrh5 antibodies and antigen-binding fragments thereof
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
WO2020039321A3 (en) Anti-gdf15 antibodies, compositions and methods of use
WO2021231237A3 (en) Antibodies for sars-cov-2 and uses thereof
GEP20227392B (en) Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
MY194997A (en) Anti-ccr7 antibody drug conjugates
NO20082167L (no) Anti-Myostatin-antistoffer
JOP20210297A1 (ar) مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
PH12022553035A1 (en) Anti-phf-tau antibodies and uses thereof
UA130540C2 (uk) Композиція антитіла b7-h4
WO2021212049A3 (en) Anti-sars-cov-2 monoclonal antibodies
MX2020010724A (es) Metodos para preparar composiciones proteicas estables.
ZA202309516B (en) Anti-ccr8 antibodies
PH12022552371A1 (en) Anti-interleukin-33 antibodies and uses thereof
PH12020551373A1 (en) Anti-phf-tau antibodies and uses thereof
WO2016193872A3 (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
MX2023011339A (es) Anticuerpos anti-tau y usos de estos.
PH12022550277A1 (en) Biopharmacuetical compositions and related methods
MX2023014984A (es) Anticuerpos anti-csp.
GEP20237484B (en) Antibody variants
MY207830A (en) Antigen binding proteins
WO2020182984A3 (en) Non-consensus glycosylation of bispecific antibodies